





## Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders

Kimia Kardani<sup>1</sup> , Azam Bolhassani<sup>1\*</sup> , Mona Kardani<sup>2</sup> , Elnaz Agi<sup>2</sup> 

<sup>1</sup>Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; <sup>2</sup>Iranian Comprehensive Hemophilia Care Center, Tehran, Iran

### ARTICLE INFO

#### Review Article

**Keywords:** SARS-CoV-2, COVID-19, Liver disorders, Hepatitis, Mechanism of action

Received: 12 Jun. 2020

Received in revised form: 06 Aug. 2021

Accepted: 11 Aug. 2021

DOI: 10.52547/JoMMID.9.3.122

#### \*Correspondence

**Email:** azam.bolhassani@yahoo.com;

A\_bolhasani@pasteur.ac.ir

**Tel:** +982166465132

**Fax:** +9866953311 Ext. 2240

© The Author(s)



### ABSTRACT

The coronavirus infectious disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a severe global health challenge. The primary target for this virus is the lung. However, SARS-CoV-2 can also attack other organs, including the kidney and liver. Some COVID-19 case reports demonstrated elevated liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin. Indeed, higher levels of liver enzymes occur in severe cases compared with mild to moderate cases. The relationship between liver injury and COVID-19 might be due to various possible reasons such as reactivation of pre-existing liver disease, viral replication in hepatic cells causing direct cytotoxicity, liver ischemia and hypoxia, cytokine storm, and drug-induced liver injury (DILI). Thus, hepatitis prevention and care services are necessary during the COVID-19 pandemic. For instance, drugs that might reactivate hepatitis B should not be prescribed for treating COVID-19. Generally, the long-term effects of SARS-CoV-2 on human health and various organs are not well understood. This review briefly discusses the relationship between SARS-CoV-2 and liver injury (hepatitis), coinfection of hepatitis and COVID-19, and SARS-CoV-2 infection in autoimmune hepatitis.

### INTRODUCTION

The coronavirus infectious disease-2019 (COVID-19) is caused by a new member of the *Coronaviridae* family, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This novel virus was primarily isolated from an infected individual in Wuhan city, China, in December 2019 [1]. Common symptoms associated with COVID-19 are fatigue, dry cough, fever, loss of smell, stuffy nose, loss of taste, and pharyngitis. Older patients, particularly with diabetes mellitus, coronary heart disease, and hypertension, are known as high risks of lethal disease progress with a mortality rate of more than 50%, while the mortality rate of the disease was about 2-5% in the general population [2, 3]. Although the primary target for SARS-CoV-2 is the lung, this virus can invade several other organs such as the kidneys, cardiovascular system, and liver [4].


Individuals suffering from COVID-19 may establish different degrees of liver dysfunction/injury. About 11% of subjects with COVID-19 infection had liver comorbidities [5]. In addition, COVID-19 could trigger liver injury with elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase

(ALT) in 35% and 28% of patients, respectively. These changes predominantly occur in individuals admitted to the intensive care units (ICU) [6-8]. In another study, the ALT and AST  $\geq 40$ U/L were observed in 22.2% and 21.3% of patients, respectively [9]. Enhanced liver enzymes were more frequent in males and severe disease conditions compared to mild cases. Also, low levels of albumin are a marker of severe infection and poor prognosis [10]. **Figure 1** indicates the possible causes of non-viral and viral hepatitis and SARS-CoV-2 effects on the liver.

World Health Organization (WHO) aims to eliminate viral hepatitis until 2030, which means the number of newly infected subjects, and related mortality should be reduced by 90% and 65%, respectively. This program covers various approaches, including diagnosis, treatment, vaccination against hepatitis B virus (HBV), preventing transmission from mother to child, and blood safety [11, 12]. Although scientists have recently focused on developing effective drugs and vaccines for COVID-19, other diseases and pathogens should be considered, as well [13]. Unfortunately, some agents such as social

distancing may impact on diagnosis and treatment of other diseases. Enhancing public awareness plays a vital role in viral hepatitis elimination programs, resulting in more cases [14]. The long-term effects of COVID-19 are still unknown. As the number of infected people soars, more abnormalities in liver function are observed [15-17]. Indeed, SARS-CoV-2 uses the angiotensin-2 converting enzyme (ACE2) receptor to attack the host cells. *Ex vivo*

studies indicated that SARS-CoV-2 could selectively target the liver, especially cholangiocytes, through ACE2, and thus hepatobiliary injury is probable [18]. Moreover, lymphopenia occur in 63%-70.3% of COVID-19 patients [19]. In severe cases of COVID-19, liver dysfunction was associated with significant activation of coagulative and fibrinolytic pathways and altered profiles of platelets, neutrophils, and lymphocytes [20].



**Fig. 1.** The possible causes of non-viral and viral hepatitis, and the proposed approaches of SARS-CoV-2 effects on liver

On the other hand, chronic liver disease patients with impaired immunity due to classical hepatitis viruses, other hepatotropic virus infections, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis were more susceptible to COVID-19 [21]. There are different treatments for COVID-19; some might be associated with hepatotoxicity. Further studies should focus on the causes of liver injury in COVID-19 and the effect of existing liver-related comorbidities on the treatment of COVID-19 [22]. The reports showed that SARS-CoV-2 might induce apoptosis in liver cells and increase inflammatory

mediators like IL-1, IL-6, and IL-10, resulting in damaging hepatocytes or hepatic steatosis. The fatty liver can influence the severity of COVID-19 [23]. Herein, we will summarize and discuss the relationship between hepatitis or liver injury and SARS-CoV-2 infection.

#### Characteristics and Pathogenesis of SARS-CoV-2

Coronaviruses (CoVs) are enveloped positive-sense single-stranded RNA viruses extensively distributed in mammals such as humans, leading to human respiratory tract or animal intestinal infections [24-26]. The CoVs are

serologically and genotypically classified into four main subfamilies, i.e.,  $\alpha$ -coronavirus,  $\beta$ -coronavirus,  $\gamma$ -coronavirus, and  $\delta$ -coronavirus. The  $\alpha$ -coronavirus and  $\beta$ -coronavirus can cause infection in humans [27, 28].

The SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV) and SARS-CoV-2 are members of  $\beta$ -coronavirus [29]. Furthermore, SARS-CoV and SARS-CoV-2 share ~79% genome sequence identity [30]. The SARS-CoV-2 has 5' (265 nucleotides) and 3' (229 nucleotides) terminal sequences common among  $\beta$ -coronaviruses. The genomic RNA of SARS-CoV-2 codes both structural and non-structural proteins that are responsible for diverse functions. The 5' terminal region of the genomic RNA contains accessory genes encoding the non-structural proteins that contribute to genome transcription and replication [31-33]. Moreover, the 3' terminal region of the genomic RNA encodes structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins [34-36].

The S protein is responsible for identifying and binding to C-type lectin (L-SIGN or CD209L) and angiotensin I converting enzyme 2 (ACE2) receptor (10-fold greater affinity than SARS-CoV), and invades the host cell through clathrin-mediated endocytosis [37-39]. Subsequently, the virus internalization occurs, and the virus recruits the host cell's reproductive machinery to generate more viral copies, then infect other host cells. Additionally, the virus recruits protein cleaving enzymes, cofactors, furin, and transmembrane proteases serine 2 (TMPRSS2) to cleave viral S protein and facilitate the virus-cell interaction [40, 41]. **Figure 2** shows the schematic model of the SARS-CoV-2 life cycle in the host liver cells.

### Liver dysfunction and Hepatitis

The liver is a master gland of the body that conducts critical functions in cell homeostasis [42-44]. The metabolism of lipids, carbohydrates, and amino acids happens in the liver. Also, this organ detoxifies xenobiotics and endogenous residues. The liver can also support the digestive and hematopoietic systems. On the other hand, the liver acts as an immune-vigilant element and generates acute-phase proteins in inflammatory responses [21, 44-47]. The rate of people suffering from liver dysfunction is increasing globally. Indeed, liver dysfunction is the 9<sup>th</sup> leading cause of death in high-middle and low-middle income countries [48]. Moreover, hepatitis is a general term involving the inflammation of the liver established by wide-range reasons comprising both non-communicable (e.g., drugs, autoimmune diseases, alcohol, fatty liver, and metabolic diseases) and communicable (e.g., bacterial, parasitic, fungal, and viral pathogens) diseases [49, 50]. Hepatitis with a non-viral origin is emerging as a significant threat to public health. Several etiologies such as metabolic disorders, alcohol abuse, nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), insufficient and imbalanced

diet, and excessive drug use [51-54] contribute to the development of chronic cirrhosis and hepatocellular carcinoma (HCC) in certain patients [55-57]. Viral hepatitis is caused by hepatotropic viruses such as hepatitis C virus (HCV), hepatitis B virus (HBV), hepatitis A virus (HAV), hepatitis D virus (HDV), and hepatitis E virus (HEV). These viruses can increase liver disease with the sign of nausea, fatigue, abdominal pain, and malaise jaundice [49, 50]. In 2015, 1.34 million deaths occurred due to viral hepatitis. Most of the viral hepatitis deaths in 2015 were due to chronic liver diseases (~720,000 deaths for cirrhosis) and primary liver cancer (~470,000 deaths for hepatocellular carcinoma) [58].

### Hepatotropic viruses


Hepatitis C virus (HCV) belongs to the genus *hepacivirus* in the *Flaviviridae* family. HCV has an enveloped positive-sense single-stranded RNA genome containing about 0.6 kb nucleotides [59]. The RNA genome of HCV encodes ten viral proteins such as structural proteins (Core, E1, and E2) and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B, and p7) [60, 61]. In addition to hepatocytes, the primary target cells, infection of dendritic cells (DCs) and B-cells have also been reported [62]. Various cellular factors such as CD81, scavenger receptor type B1 (SRB), and claudin-1 are required for virus entry into hepatocytes [63, 64]. Inflammatory immunity against viral core proteins and the antigens expressed on the surface of HCV-infected hepatocytes leads to hepatocyte injury [65]. Moreover, acute HCV (AHC) infections are commonly asymptomatic [66]. HCV infections progress to chronic in approximately 70%-80% of infected individuals. On the other hand, spontaneous viral clearance (SVC) occurs in 25%-40% of individuals within 12 months of infection [64, 67, 68]. The cases with cirrhosis and chronic hepatitis C (CHC) are at a high risk of hepatocellular carcinoma and liver failure [64].

Hepatitis B virus (HBV) belongs to the *Hepadnaviridae* family [69, 70], and its genome contains a partially double-stranded relaxed circular DNA (rcDNA) with approximately 3200 bp nucleotides. The rcDNA of HBV encodes four overlapping frame-shifted reading frames, including the surface (S) gene, core (C) gene, X (X) gene, and polymerase (P) gene [71, 72]. After virus entry, the rcDNA is delivered to the nucleus and changed into complete double-stranded DNA [73]. However, other genomic forms of DNA persist. Moreover, the mutated viral proteins are produced to contribute to hepatocarcinogenesis [74]. The probability of HBV infection relies on age. In most cases, perinatal infection results in chronicity, while the infection in adults in most cases is controllable. This difference is might be due to various immune maturities between young children and adults [75].

Hepatitis A virus (HAV) establishes only acute hepatitis and belongs to the *Hepatovirus* genus in the

*Picornaviridae* family. HAV has a positive-sense single-stranded RNA genome containing about 7500 nucleotides and includes a single large open reading frame encoding a polyprotein. The RNA genome of HAV is packaged

with icosahedral capsid composed of sixty copies of each VP1, VP2, and VP3 protein, which are major structural proteins of HAV [76].



**Fig.2.** Schematic model of SARS-CoV-2 life cycle in the host liver cells: The spike (S) protein of SARS-CoV-2 is first attached to host liver cells (hepatocytes) through ACE2 receptor. Then, the transmembrane serine protease 2 (TMPRSS2) cleaves the S protein. Next, the entry of the virus occurs. After virus uncoating, the viral RNA genome (vgRNA) is released, and then the ribosome translates vgRNA into pp1a, and pp1ab which is cleaved into non-structural proteins (nsps). Subsequently, assembly of the replication/transcription complex (vRTC) of the virus, nsp6 (in yellow color), leads to the formation of autophagosome for providing a place for viral replication. In addition, replication of vgRNA can take place in double-membrane vesicles (DMV). Inhibition of autophagosome/lysosome expansion mediated by nsp6 can avoid degradation of the virus. Moreover, the synthesized structural and accessory proteins are assembled to form the nucleocapsid and envelope of the virus at the ER-Golgi compartment. Finally, the mature virions are released via the exploitation of the vesicular system of the host. Autophagosomes and DMV can be utilized by the virus for exocytosis and releasing the mature virions.

Hepatitis D virus (HDV) can only infect people who already are HBV-infected [77], but the proportion of deaths because of HBV in which HDV can be a cofactor has not yet been estimated by WHO. In 1980, HDV was shown to rely on envelope proteins of HBV for assembly of progeny virus and infection of susceptible cells [78]. HDV contains a circular genomic RNA of ~1700 bp size, a genome smaller than other infectious viruses. HDV exhibits similarities to non-coding RNAs recognized as viroids that are pathogenic for plants [79]. Circular genomic RNA of HDV encodes one protein (S-HDAg). During viral replication, S-HDAg is required to accumulate processed HDV RNA transcripts [80] and synthesize a longer form of S-HDAg (large HDAg or L-

HDAg). The L-HDAg form contains 19 extra amino acids at its C-terminal and is required for the new virus assembly mediated by the envelope proteins of HBV [79, 81].

Hepatitis E virus (HEV) causes primarily acute hepatitis and belongs to the *Orthohepevirus* genus in the *Hepeviridae* family. The genus *Orthohepevirus* includes A, B, C, and D species, among which only the species A is transmitted to humans [82, 83]. The genome of HEV is a positive-sense single-stranded RNA of ~7.5 kb long containing a short 5'-non-coding region capped with 7-methylguanosine, a short 3' non-coding region that ends in poly (A) tail, and three open reading frames [84]. As known, infection with HEV causes an acute, self-limiting

form of liver inflammation. Acute hepatitis can be promoted to cirrhosis, chronic hepatitis, liver failure, and acute-on-chronic liver failure [85].

### How can SARS-CoV-2 influence the liver?

The liver biopsy specimens of people who died of severe COVID-19 infection indicated mild lobular and portal activity and moderate microvascular steatosis suggesting the injury by either drug-induced injury or SARS-CoV-2 [86]. The significant liver injury patterns of SARS-CoV-2 occur in chronic liver disease (CLD) patients, with or without cirrhosis. The CLD patients with diabetes and obesity were more susceptible and should be intensely monitored for COVID-19 infection [87]. Up to now, various mechanisms have been proposed: (A) reactivation of pre-existing liver disease; the patients with pre-existing chronic liver disease are more susceptible to liver injury caused by SARS-CoV-2 [88]. In addition, certain drugs such as tofacitinib, dexamethasone, baricitinib, and tocilizumab likely cause HBV reactivation and subsequent deterioration of liver function [89-91]. (B) Direct cytotoxicity via viral replication in hepatic cells; SARS-CoV-2 binds to the target cells via angiotensin-converting enzyme-2 (ACE2) receptors, and this receptor is expressed in the liver, especially in biliary epithelial cells [92]. The elevation of ALT and AST levels has been observed in COVID-19 patients, indicating some degrees of liver damage caused by SARS-CoV-2 [93]. (C) Liver ischemia and hypoxia; the COVID-19 causes respiratory failure. Thus, anoxia leads to hypoxic hepatitis in severe cases. In detail, the liver is protected from ischemic damage via two routes of oxygenation, i.e., redundant blood flow from the hepatic artery and the portal vein. The hepatic artery and the portal vein contribute to 20%-25% and 75%-85% of liver blood supply, respectively [94]. The hepatic blood flow is reduced during systemic stress and is inadequate to provide the liver requirements. The inability of the liver to increase the oxygen extraction sufficiently results in hepatocellular hypoxia. Hypoxic liver damage remarkably elevates calcium overloading, aminotransferase, metabolic acidosis, and changes the mitochondrial membrane permeability [94, 95]. (D) Cytokine storm: extreme physiological stress may disrupt liver functions such as detoxification of the intestines-originated xenobiotics in portal blood. One of these solid physiological stresses is cytokine storm which led to a hyper-inflammatory situation followed by organ damage [96-98]. In this regard, an uncontrolled overproduction of inflammatory cytokines, i.e., cytokine storm, results in acute respiratory distress syndrome (ARDS) and acute lung injury. The release of high levels of multiple cytokines, including IL-10, IL-7, IL-6, IL-2, GM-CSF, IP-10, TNF- $\alpha$ , MIP-1 $\alpha$ , and MCP-1, occur in individuals with severe COVID-19 [96, 97]. Meanwhile, the immune system tries to suppress and eradicate the SARS-CoV-2 virus, and immunopathologic damage happens in organs

and tissues [99]. The high levels of inflammatory cytokines result in more significant tissue and organ injury, and finally, death. Hence, a cytokine storm could potentially damage specific organs such as the lungs, gut, and liver resulting in death [95, 100]. In addition, the inflammation biomarkers such as serum ferritin, IL-2, IL-6, C-reactive protein (CRP), D-dimer, and lactate dehydrogenase (LDH) are significantly raised in severe COVID-19 cases [101, 102].

(E) Drug-induced liver injury (DILI): various medications, including antivirals, antibiotics, steroids, and antipyretics, are utilized to treat COVID-19 or alleviate the symptoms. Some of these medications for COVID-19 are potentially hepatotoxic in some instances. Histology demonstrated mild hepatic inflammation and moderate microvascular steatosis, likely due to drug-induced liver injury [100]. These drugs are paracetamol, remdesivir, oseltamivir, tocilizumab, arbidol (also known as Umifenovir), chloroquine, hydroxychloroquine, and lopinavir/ritonavir [5, 103, 104]. Moreover, while acetaminophen was confirmed as the most common cause of acute liver failure and toxicity, this medication is still a choice to treat fever and myalgia associated with COVID-19 [104, 105]. The Food and Drug Administration (FDA) approved remdesivir to treat individuals with COVID-19 on October 22, 2020 [106, 107]. Previously, remdesivir was deployed for the treatment of Ebola and hepatitis C (no appropriate success). Although no curative, it reduces the recovery time in hospitalized COVID-19 patients with low respiratory tract infections [108, 109]. Furthermore, the reports indicated elevated liver enzymes in COVID-19 patients receiving remdesivir [106, 107]. DILI was reported in 37.2% and 15.2% of cases treated with lopinavir/ritonavir and remdesivir, respectively [110].

COVID-19-induced hepatitis (CIH), defined as "benign new transient hepatitis" in a SARS-CoV-2 patient, was characterized by different symptoms including gradual onset, elevated AST and ALT, dilated sinusoids with lymphocytic infiltration of liver parenchyma, non-obstructive jaundice, stable underlying liver disease, and no radiological new hepatobiliary changes [111]. On the other hand, due to existing metabolic abnormalities, nonalcoholic fatty liver disease (NAFLD) seems to contribute as a potential risk factor to severe SARS-CoV-2 infection. This is because of the interaction of chronically active inflammatory pathways in NAFLD and COVID-19-associated acute cytokine storm. The relationship between NAFLD and severe COVID-19 was studied independent of obesity as a significant risk factor for both NAFLD and COVID-19. NAFLD showed to be a significant predictor of severe COVID-19 even after adjusting for the presence of obesity. The exact relationship between liver fat and COVID-19 should be further investigated [23].

**Atypical elevated liver enzymes in COVID-19 patients**

Enhanced liver enzymes due to hepatic injury are common among COVID-19 cases with and without chronic liver diseases [112-116]. For the first time, Chen *et al.* (2020) reported abnormal elevation of liver enzymes. Among 99 COVID-19 patients, ~43.4% had enhanced serum levels of AST, ALT, and LDH. Most of the cases had a mildly elevated aminotransferase, and only one patient had high levels of ALT (7590 U/L) and AST (1445 U/L) [117]. In another report, among 12 COVID-19 severe cases, only one had an abnormal elevation of liver enzymes (AST: 62 U/L; ALT: 107 U/L) [118]. Moreover, in Wuhan, among 305 COVID-19 cases, 119 had enhanced ALT, AST, and bilirubin levels. Also, 19 and 24 cases had increased AST (80 U/L) and ALT (80 U/L) levels, respectively, whereas only six had an elevated bilirubin level [112]. Also, the first Chinese COVID-19 patient described in the USA with details of liver function tests exhibited enhanced AST, and ALT serum levels from 37 to 89 U/L and from 68 to 203 U/L, respectively [113].

Recently, several reports demonstrated the relationship of severity of COVID-19 infection with abnormal liver biochemistry. A report from 1099 COVID-19 patients in China showed that most of the abnormal levels of liver enzymes occurred in severe patients, i.e., 28.1% and 39.4% of cases had ALT>40 U/L and AST>40 U/L, respectively [9]. Also, among 265 patients in Shanghai, AST and ALT serum levels in severe cases were remarkably higher than those in mild to moderate patients [114]. The cases admitted to the ICU showed higher AST, ALT levels, and total bilirubin [6, 7]. The pathological characteristics of liver changes, e.g., mild lobular and portal activity and moderate microvascular steatosis in the liver, were related to COVID-19 [86]. In fact, the potential liver damage was strongly associated with coronavirus infection [115, 116]. The HBV and HCV infections were described in COVID-19 cases; in 5700 hospitalized COVID-19 patients in the USA, HBV and HCV infections were found in 0.1% and <0.1% of cases, respectively [119]. Furthermore, among 1099 hospitalized patients (n=1099) in Wuhan, 2.1% of cases were HBV-infected, comprising ~2.4% of non-severe and ~0.6% of severe subjects [9]. In another study in China, among 123 COVID-19 cases, 15 (12.2%) had HBV-infection [120]. In an observational study in two COVID-19-designated hospitals in Wuhu, Anhui province, China, two had HBV infection among 31 corticosteroid-treated COVID-19 cases. The data indicated a delayed clearance of SARS-CoV-2 in cases with HBV infection [121]. On the other hand, the COVID-19 pandemic has affected the programs and efforts to eliminate viral hepatitis globally. Mathematical models estimated excess mortality of 44,800 for HCC and 72,300 for liver-related deaths with a one-year delay of HCV treatment administration [122]. Patients with SARS-CoV-2 and HBV coinfection showed more severe monocytopenia and thrombocytopenia and

had a more disturbing hepatic function in albumin production and lipid metabolism [123]. Generally, hepatic symptoms and fever, cough, and dyspnea are common among HBV and HCV patients infected with COVID-19, with a significant risk of mortality was among these individuals. Since about 290 million and 71 million people are affected with HBV and HCV worldwide, respectively, the number of patients with SARS-CoV-2 and HBV and/or HCV co-infections will likely increase [124].

**Treatment approaches of cases co-infected with COVID-19 and Hepatitis**

Antiviral treatments are first given to COVID-19 cases with mild liver biochemical abnormalities to block viral replication, decrease inflammation, and improve immunity. The enzyme-lowering and liver-protecting drugs are not recommended [125]. In COVID-19 cases with the background of HCV infection, it is more reasonable to postpone HCV therapy until COVID-19 clearance. Moreover, there is a risk of HBV reactivation associated with medications including tocilizumab and corticosteroids, used in the context of COVID-19. Utilizing tocilizumab and prednisone reactivate HBV infection; hence, preventive measures should be adopted against this reactivation [126, 127]. The less toxic medications prescribed for treating COVID-19 patients with advanced liver disease including remdesivir, nitazoxanide+sofosbuvir, ivermectin, tocilizumab, convalescent plasma, and low molecular weight heparin in certain conditions. The advanced liver disease led to portal hypertension and splenomegaly, immune dysfunction, and impaired T cell function. Therefore, when a cytokine storm occurs due to an immune response to COVID-19, the mortality rate can increase in patients with advanced liver disease [98].

As known, several new direct-acting antiviral (DAAs) combinations, including elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir, have been approved for the HCV treatment. The newly approved DAA regimens may be prescribed alongside other medications simultaneously, increasing the potential of pharmacokinetic interactions. Therefore, managing drug-drug interactions (DDIs) with DAAs should be considered a vital issue in HCV therapy. Concerning DDIs, these newly approved DAA regimens were safe [128]. Sofosbuvir, ribavirin, and remdesivir were reported as potent drugs against COVID-19, which bind to COVID-19 RNA-dependent RNA polymerase (RdRp) [129]. Chen *et al.* [126] indicated that the Eplclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) drugs were very effective due to their dual inhibitory actions on two viral enzymes [126].

**COVID-19 and autoimmune hepatitis**

The possible pathogenic mechanisms linking cirrhosis with severe COVID-19 include increased systemic inflammation, cirrhosis-associated immune dysfunction, coagulopathy, and intestinal dysbiosis. Abnormal liver biochemistry values are common in COVID-19 patients. However, liver transplant recipients showed no increased risk of mortality following SARS-CoV-2 infection [130]. Chronic immunosuppression was associated with increased viral infections. However, little was known of the association between immunosuppression and SARS-CoV-2 infection. Gerussi *et al.* (2020) studied the clinical course of patients with immunosuppressed autoimmune hepatitis (AIH) during COVID-19 infection in Italy. Patients under immunosuppressive therapy for AIH showed a disease course similar to that in the non-immunosuppressed population during COVID-19 infection [131]. The pilot clinical experiences demonstrated that immunosuppressed patients' morbidity and mortality rates did not differ significantly from the general population [132]. However, Marjot *et al.* [2021] showed that AIH patients were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of chronic liver disease (CLD) and matched cases without the liver disease [133].

In conclusion, the reports showed that some COVID-19 patients experience various degrees of liver function abnormalities. Several mechanisms could affect the liver in cases with COVID-19, such as reactivation of pre-existing liver disease, viral replication in hepatic cells causing direct cytotoxicity, liver ischemia and hypoxia, cytokine storm, and drug-induced liver injury. Activation of the immune system and cytokine storm play a prominent role in an immune-mediated process of hepatic injury in COVID-19. The control of cytokine dysregulation at the first stages can be helpful to limit the disease progression. In COVID-19, the liver is the most affected organ apart from the respiratory system; thus, other therapeutic approaches are required for severe cases, particularly those with pre-existing liver disease. Hence, mechanistic understanding of the relationship of SARS-CoV-2 infection with liver injury is vital for the clinical practice of managing COVID-19 patients with hepatic injury. Hepatitis prevention and care services are necessary during the COVID-19 pandemic, such as vaccination of newborns and infants against hepatitis B. Further studies should concentrate on the mechanisms of liver injury in COVID-19 and the impact of liver diseases on COVID-19 treatment in the future.

**ACKNOWLEDGMENT**

We express our gratitude to Dr. Arash Nikyar for editing the manuscript.

**CONFLICT OF INTEREST**

We declare that there is no conflict of interest associated with this manuscript.

**REFERENCES**

1. Kardani K, Bohassani A. Vaccine development against SARS-CoV-2: from virology to vaccine clinical trials. *Coronaviruses*. 2020; 2 (2): 159-71.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020; 395 (10229): 1054-62.
3. Shenoy N, Luchtel R, Gulani P. Considerations for target oxygen saturation in COVID-19 patients: are we undershooting? *BMC Med*. 2020; 18: 260.
4. Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy: A letter to editor. *Arch Acad Emerg Med*. 2020; 8 (1): e17.
5. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol*. 2020; 5 (5): 428-30.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395 (10223): 497-506.
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020; 323 (11): 1061-9.
8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020; 395 (10223): 507-38.
9. Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. *J Emerg Med*. 2020; 58 (4): 711-2.
10. Liu W, Tao ZW, Lei W, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J*. 2020; 133 (9): 1032-8.
11. Mendlowitz AB, Naimark D, Wong WL, Capraru C, Feld JJ, Isaranuwatthai W, et al. The emergency department as a setting-specific opportunity for population-based hepatitis C screening: an economic evaluation. *Liver Int*. 2020; 40 (6): 1282-91.
12. Hutin YJF, Bulterys M, Hirschall GO. How far are we from viral hepatitis elimination service coverage targets? *J Int AIDS Soc*. 2018; 21 (Suppl Suppl 2): e25050.
13. Horton R. Offline: a dangerous virus, but not the one you think. *Lancet*. 2020; 395 (10227): 854.
14. Karimi-Sari H, Tajik M, Bayatpoor ME, Alavian SM. Increasing the awareness of the general population: an important step in elimination programs of viral hepatitis. *Am J Gastroenterol*. 2017; 112 (2): 393-5.

15. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): A perspective from China. *Radiology*. 2020; 200490.
16. Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy. *Zhonghua Gan Zang Bing Za Zhi*. 2020; 28 (2): 97-9.
17. Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. *Lancet Gastroenterol Hepatol*. 2020; 5 (5): 425-7.
18. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. *United European Gastroenterology Journal*. 2020; 8 (5): 509-19.
19. Li L, Li S, Xu M, Yu P, Zheng S, Duan Z, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. *MedRxiv Preprint*. 2020. doi: 10.1101/2020.02.28.20028514.
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020. 323 (11): 1061-1069.
21. Preziosi ME, Monga SP. Update on the mechanisms of liver regeneration. *Semin Liver Dis*. 2017; 37 (2): 141-51.
22. Ridruejo E, Soz A. The liver in times of COVID-19: What hepatologists should know. *Ann Hepatol*. 2020; 19 (4): 353-8.
23. Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: A pooled analysis. *SN Compr Clin Med*. 2020; 2: 2726-9.
24. Chauhan N, Jaggi M, Chauhan SC, Yallapu MM. COVID-19: Fighting the invisible enemy with microRNAs. *Expert Rev Anti Infect Ther*. 2021; 19 (2): 137-45.
25. Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, et al. Smoking and COVID-19: Adding Fuel to the Flame. *Int J Mol Sci*. 2020; 21: 6581.
26. Yang P, Wang X. COVID-19: A new challenge for human beings. *Cell Mol Immunol*. 2020; 17 (5): 555-7.
27. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. *Adv Virus Res*. 2011; 81: 85-164.
28. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication. *Curr Top Microbiol Immunol*. 2018; 419:1-42.
29. Parvez MK. COVID-19 and coronaviral hepatitis: evidence of collateral damage. *Future Virol*. 2020; 15 (6): 325-9.
30. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. *Cell Host Microbe*. 2020; 27 (3): 325-8.
31. Chan JF, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect*. 2020; 9 (1): 221-36.
32. Masters PS. The molecular biology of coronaviruses. *Adv Virus Res*. 2006; 66: 193-292.
33. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. *Biochem Biophys Res Commun*. 2020; 525 (1): 135-40.
34. Fung TS, Liu DX. Human coronavirus: Host-pathogen interaction. *Annu Rev Microbiol*. 2019; 73: 529-57.
35. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020; 579 (7798): 270-3.
36. Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. *BioRxiv*. 2020; doi: <https://doi.org/10.1101/2020.01.24.919183>.
37. Wrapp D, Wang N, Corbett K, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 2020; 367 (6483): 1260-3.
38. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res*. 2018; 18 (2): 290-301.
39. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020; 580 (7803): E7.
40. Glowacka I, Bertram S, Müller MA, Allen PD, Soilleux EJ, Pfeerle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol*. 2011; 85 (9): 4122-34.
41. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci USA*. 2020; 117: 11727-34.
42. Knell AJ. Liver function and failure: the evolution of liver physiology. *JR Coll Physicians Lond*. 1980; 14(3): 205-8
43. Rui L. Energy metabolism in the liver. *Compr Physiol*. 2014; 4 (1): 177-97.
44. Tarasenko TN, McGuire PJ. The liver is a metabolic and immunologic organ: A reconsideration of metabolic decompensation due to infection in inborn errors of metabolism (IEM). *Mol Genet Metab*. 2017; 121 (4): 283-8.
45. Gordillo M, Evans T, Gouon-Evans V. Orchestrating liver development. *Development*. 2015; 142 (12): 2094-108.
46. Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. *Cell Mol Immunol*. 2016; 13 (3): 267-76.
47. Koo SH. Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis. *Clin Mol Hepatol*. 2013; 19 (3): 210-5.
48. World Health Organization. Brazil Health Profile 2016; <http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death>.
49. Caetano KA, Bergamaschi FP, Carneiro MA, Pinheiro RS, Araújo LA, Matos MA, et al. Hepatotropic viruses (hepatitis A, B, C, D and E) in a rural Brazilian population: Prevalence, genotypes, risk factors and vaccination. *Trans R Soc Trop Med Hyg*. 2020; 114 (2): 91-8.



50. Bashir S, Assadullah Z, Kumar A, Barik M. Correlation of hepatitis A, B, C emphasis with COVID-19: Recent advances and future prospective. In book: A Text Book of the SARS-CoV-2: Guidelines and Protocol Development, MAHI publication. 2020; 284-97.
51. Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. *Gene Expr*. 2014; 16 (2): 77-84.
52. Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. *Semin Liver Dis*. 2015; 35 (2): 146-56.
53. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. *Hepatology*. 2014; 59 (4): 1331-42.
54. Wilbur K. Non-viral hepatitis. *J Pharm Pract*. 2009; 22 (4): 388-404.
55. Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 (COVID-19) and prevalence of chronic liver disease: a meta-analysis. *Liver Int*. 2020; 40: 1316-32.
56. Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between nonalcoholic fatty liver disease and hepatocellular carcinoma. *Hepatology Res*. 2019; 5: 42.
57. Wallace MC, Friedman SL, Mann DA. Emerging and disease-specific mechanisms of hepatic stellate cell activation. *Semin Liver Dis*. 2015; 35 (2): 107-18.
58. World Health Organization. Global hepatitis report 2017.
59. Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. *Expert Rev Clin Pharmacol*. 2020; 13 (9): 1001-46.
60. Ogholikhan S, Schwarz KB. Hepatitis vaccines. *Vaccines (Basel)*. 2016; 4 (1): 6.
61. Basirnejad M, Bolhassani A, Sadat SM. The distinct role of small heat shock protein 20 on HCV NS3 expression in HEK-293T cell line. *Avicenna J Med Biotechnol*. 2018; 10 (3): 152-7.
62. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol*. 2007; 5 (6): 453-63.
63. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: Current status and remaining challenges. *J Hepatol*. 2008; 49 (4): 625-33.
64. Bartosch B, Vitelli A, Granier C, Goujon C. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. *J Biol Chem*. 2003; 278 (43): 41624-30.
65. Abdelwahab K, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. *World J Gastroenterol*. 2016; 22 (2): 862-73.
66. Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH. Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection. *Cell Host Microbe*. 2018; 24 (5): 717-30.
67. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. *J Viral Hepat*. 2006; 13 (1): 34-41.
68. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, et al. The impact of illicit drug use on spontaneous hepatitis C clearance: Experience from a large cohort population study. *PLoS ONE*. 2011; 6 (8): e23830.
69. Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018; 67 (4): 1560-99.
70. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. *Semin Liver Dis*. 2013; 33 (2): 97-102.
71. Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. *Best Pract Res Clin Gastroenterol*. 2017; 31 (3): 257-64.
72. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. *Lancet*. 1970; 1 (7649): 695-8.
73. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. *Cell*. 1986; 47 (3): 451-60.
74. Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. *Viruses*. 2017; 9 (4): 75.
75. Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. *Trends Microbiol*. 2018; 26 (1): 33-42.
76. Martin A, Lemon SM. Hepatitis A virus: From discovery to vaccines. *Hepatology*. 2006; 43 (2 Suppl 1): S164-72.
77. Farci P. Delta hepatitis: An update. *J Hepatol*. 2003; 39: S212-9.
78. Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. *J Infect Dis*. 1980; 141 (5): 590-602.
79. Flores R, Gas ME, Molina-Serrano D, Nohales MA. Viroid replication: rolling-circles, enzymes and ribozymes. *Viruses*. 2009; 1 (2): 317-34.
80. Chao M, Hsieh SY, Taylor J. Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. *J Virol*. 1990; 64 (10): 5066-9.
81. Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS. The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. *Proc Natl Acad Sci USA*. 1991; 88 (19): 8490-4. 82. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology*. 2012; 55 (4): 988-97.
83. Smith DB, Izopet J, Nicot F, Simmonds P, Jameel S, Meng XJ, et al. Update: Proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). *J Gen Virol*. 2020; 101 (7): 692-8.
84. Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. *Proc Natl Acad Sci U S A*. 1992; 89 (17): 8259-63.

85. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. *Nat Rev Dis Primers*. 2017; 3 (1): 17086.
86. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020; 8 (4): 420-2.
87. Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-El Salam S, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection. *Hepatol Int*. 2020; 14 (5): 690-700.
88. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism*. 2020; 111S: 154170.
89. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int*. 2020; 40 (6): 1278-81.
90. Hammond A, Ramersdorfer C, Palitzsch KD, Scholmerich J, Lock G. Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier. *Dtsch Med Wochenschr*. 1999; 124 (22): 687-90.
91. Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in patients with "latent" chronic hepatitis B. *Liver*. 2000; 20 (5): 415-20.
92. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *Biorxiv*. 2020; doi: <https://doi.org/10.1101/2020.02.03.931766>.
93. Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. *Lab Invest*. 2020; 100: 794-800.
94. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver injury and failure in critical illness. *Hepatology*. 2019; 70 (6): 2204-15.
95. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. *J Clin Transl Hepatol*. 2020; 8 (1): 18-24.
96. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). *Front Immunol*. 2020; 11: 827.
97. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). *MedRxiv*. 2020; doi: [10.1101/2020.02.10.20021832](https://doi.org/10.1101/2020.02.10.20021832).
98. Hanafy AS, Abd-El Salam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. *World J Gastroenterol*. 2020; 26 (46): 7272-86.
99. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. *Cytokine Growth Factor Rev*. 2020; 53: 38-42.
100. Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. *J Clin Transl Hepatol*. 2020; 8 (1): 13-7.
101. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020; 395 (10229): 1033-4.
102. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine*. 2020; 55: 102763.
103. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). *J Gen Intern Med*. 2020; 35 (5): 1545-9.
104. Boeckmans J, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: A problem of plenty or a petty point? *Arch Toxicol*. 2020; 94 (7): 1367-9.
105. Lee D. Tylenol liver damage: signs, symptoms, dosage, treatment. *MedicineNet* 2016; [www.medicinenet.com/tylenol\\_liver\\_damage/article.htm](http://www.medicinenet.com/tylenol_liver_damage/article.htm).
106. U.S. Food & Drug Administration. Remdesivir EUA letter of authorization 2020; [www.fda.gov/media/137564/download](http://www.fda.gov/media/137564/download).
107. U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. 2020; <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19>.
108. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19: Final report. *N Engl J Med*. 2020; 383 (19): 1813-26.
109. Szabo L. Chasing the elusive dream of a COVID cure. *Kaiser Health News* 2020; <https://khn.org/news/chasing-the-elusive-dream-of-a-covid-cure>.
110. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther*. 2020; 52: 584-99.
111. Gadour E, Hassan Z, Shrwani K. COVID-19 Induced Hepatitis (CIH), definition and diagnostic criteria of a poorly understood new clinical syndrome. *Gut*. 2020; 69 (1): A1-51.
112. Fang D, Ma J, Guan J, Wang M, Song Y, Tian D, et al. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. *Chin J Dig*. 2020; 12: E005.
113. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med*. 2020; 382 (10): 929-36.
114. Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, et al. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. *MedRxiv*. 2020; doi: [10.1101/2020.02.19.20025031](https://doi.org/10.1101/2020.02.19.20025031).
115. Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology*. 2004; 39 (2): 302-10.
116. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. *Gut*. 2005; 54 (7): 1024-33.

117. Chen X, Jiang Q, Ma Z, Ling J, Hu W, Cao Q, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus coinfection. *Virology*. 2020; 35 (6): 842-5.
118. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci*. 2020; 63 (3): 364-74.
119. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020; 323 (20): 2052-9.
120. Chen LF, Mo YQ, Jing J, Ma JD. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. *Int J Rheum Dis*. 2017; 20 (7): 859-69.
121. Zha L, Li S, Pan L, Tefsen B, French N, Chen L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust*. 2020; 212 (9): 416-20.
122. Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global HCV elimination efforts. *J Hepatol*. 2021; 74 (1): 31-6.
123. Liu R, Zhao L, Cheng X, Han H, Li C, Li D, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection-a retrospective study. *Liver Int*. 2021; 41 (4): 720-30.
124. Mirzaie H, Vahidi M, Shokoohi M, Darvishian M, Sharifi H, Sharafi H, et al. COVID-19 among patients with hepatitis B or hepatitis C: A systematic review. *MedRxiv*. doi: <https://doi.org/10.1101/2020.10.22.20216317>.
125. Tian D, Ye Q. Hepatic complications of COVID-19 and its treatment. *J Med Virol*. 2020; 92 (10): 1818-24.
126. Chen YW, Bennu Yiu CP, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. *F1000Res*. 2020; 9: 129.
127. Reddy KR, Beavers KL, Hammond SP. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology*. 2015; 148 (1): 215-9.
128. Gao LH, Nie QH, Zhao XT. Drug-drug interactions of newly approved direct-acting antiviral agents in patients with hepatitis C. *Int J Gen Med*. 2021; 14: 289-301.
129. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sci*. 2020; <https://doi.org/10.1016/j.lfs.2020.117477>.
130. Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. *Nat Rev Gastroenterol Hepatol*. 2021; 18 (5): 348-64.
131. Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, et al. Coronavirus disease 2019 in autoimmune hepatitis: A lesson from immunosuppressed patients. *Hepatol Commun*. 2020; 4 (9): 1257-62.
132. Thng ZX, Smet MD, Lee CS, Gupta V, Smith, JR, McCluskey PJ, et al. COVID-19 and immunosuppression: A review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. *Br J Ophthalmol*. 2021; 105 (3): 306-10.
133. Marjot T, Buescher G, Sebode M, Barnes E, Barritt AS, Armstrong MJ, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. *J Hepatol*. 2021; 74 (6): 1335-43.

**Cite this article:**

Kardani K, Bolhassani A, Kardani M, Agi E. Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders. *J Med Microbiol Infect Dis*, 2021; 9 (2): 122-132. DOI: 10.52547/JoMMID.9.3.122